Osteoporosis — MCQs
Treatment of post menopausal osteoporosis are all EXCEPT
Estrogen administration in a menopausal woman increases the:
Non-hormonal drug to prevent postmenopausal osteoporosis is:
Which of the following is not a known cause of osteoporosis?
A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
Which clinical sign is consistently present in all bone fractures?
Osteoporosis in menopause typically affects
The compression fracture is commonest in
Which of the following is not typically associated with osteogenesis imperfecta?
A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
Osteoporosis Indian Medical PG Practice Questions and MCQs
Question 1: Treatment of post menopausal osteoporosis are all EXCEPT
- A. Estrogen
- B. Magnesium and Zinc (Correct Answer)
- C. Calcium, Vit D supplementation
- D. Raloxifene
Explanation: ***Magnesium and Zinc*** - While **magnesium** and **zinc** are essential for overall health, their role as primary therapeutic agents for established postmenopausal osteoporosis is **unproven** and is not standard treatment. - They are considered **trace elements** and their deficiency can affect bone health, but supplementation alone is not sufficient to treat osteoporosis. *Estrogen* - **Estrogen replacement therapy** was historically used for postmenopausal osteoporosis due to its role in preventing bone loss, but its use is now limited due to **adverse effects** like increased risk of breast cancer and cardiovascular events [1]. - It is still considered in select cases for symptom relief and bone health, but generally at the lowest effective dose for the shortest duration [1]. *Calcium, Vit D supplementation* - **Calcium and Vitamin D supplementation** are fundamental components of osteoporosis management by supporting bone mineralization and calcium homeostasis [2]. - Adequate intake is critical for both **prevention** and **treatment**, often used in conjunction with other pharmacologic agents [2]. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen agonist on bone, thereby reducing bone resorption and increasing bone mineral density [1]. - It is used in the treatment and prevention of postmenopausal osteoporosis, with the added benefit of reducing the risk of invasive breast cancer [1].
Question 2: Estrogen administration in a menopausal woman increases the:
- A. Bone mass (Correct Answer)
- B. Gonadotropin secretion
- C. Muscle mass
- D. LDL cholesterol
Explanation: ***Bone mass*** - Estrogen plays a crucial role in maintaining **bone density** by inhibiting osteoclast activity and promoting osteoblast function. - In menopausal women, estrogen administration counteracts bone loss and thus **increases bone mass**, reducing the risk of osteoporosis. *Gonadotropin secretion* - In menopausal women, **gonadotropin-releasing hormone (GnRH)** and subsequent **FSH and LH levels are elevated** due to the absence of ovarian estrogen feedback. - Estrogen administration would exert a **negative feedback** on the hypothalamus and pituitary, thereby **decreasing**, not increasing, gonadotropin secretion. *Muscle mass* - While estrogen has some anabolic effects, **androgens** (like testosterone) are the primary hormones responsible for significantly increasing muscle mass. - Estrogen administration to menopausal women is not a primary intervention for increasing muscle mass; its effects on this parameter are generally **modest or negligible**. *LDL cholesterol* - Estrogen generally has a **favorable effect on lipid profiles**, typically leading to a **decrease in LDL cholesterol** and an increase in HDL cholesterol. - Therefore, estrogen administration would generally **reduce**, not increase, LDL cholesterol levels.
Question 3: Non-hormonal drug to prevent postmenopausal osteoporosis is:
- A. Alendronate (Correct Answer)
- B. Estrogen
- C. Raloxifene
- D. Teriparatide
Explanation: ***Alendronate*** - **Alendronate** is a **bisphosphonate**, a class of non-hormonal drugs that inhibit **osteoclast** activity, thereby reducing bone resorption and increasing bone density. - It is a first-line treatment for **postmenopausal osteoporosis** and is effective in preventing fractures. *Estrogen* - **Estrogen** is a **hormonal therapy** used to prevent postmenopausal osteoporosis. - However, its use is associated with increased risks of **thromboembolism**, stroke, and certain cancers. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)**. - While it has estrogen-like effects on bone, it is technically considered a **hormonal agent** because its mechanism of action involves interacting with estrogen receptors. *Teriparatide* - **Teriparatide** is a **parathyroid hormone (PTH) analog**, making it a **hormonal agent** that stimulates **osteoblast** activity to promote new bone formation. - It is an anabolic agent typically reserved for severe osteoporosis or those who have failed other therapies due to its injectable administration and higher cost.
Question 4: Which of the following is not a known cause of osteoporosis?
- A. Sarcoidosis
- B. Old age
- C. Hypoparathyroidism (Correct Answer)
- D. Steroid therapy
Explanation: ### Hypoparathyroidism - This condition leads to **low parathyroid hormone (PTH)** levels, resulting in **decreased serum calcium** and **increased serum phosphate**. - While it can affect bone metabolism, severe cases typically present with **increased bone mineral density** or **osteosclerosis**, not osteoporosis, due to reduced bone resorption. *Sarcoidosis* - This granulomatous disease can cause **hypercalcemia** due to extrarenal production of **calcitriol** (1,25-dihydroxyvitamin D) by activated macrophages. - The resulting hypercalcemia and prolonged high calcitriol levels can lead to **increased bone turnover** and **osteoporosis** [4]. *Old age* - Bone density naturally declines with age, especially after menopause in women due to **estrogen deficiency** [3]. - This age-related bone loss is a primary factor in the development of **primary osteoporosis** [2]. *Steroid therapy* - **Glucocorticoid-induced osteoporosis** is a common cause of secondary osteoporosis [1]. - Steroids decrease osteoblast activity, increase osteoclast activity, and impair calcium absorption, all contributing to **bone loss** [1].
Question 5: A female is on hormone replacement therapy for her menopausal symptoms. She is worried about her bone strength because her mom and sister had osteoporosis after the age of 50. All are given for prevention of osteoporosis along with hormonal replacement therapy, EXCEPT:
- A. Calcium
- B. Vitamin-E (Correct Answer)
- C. Vit.D
- D. None of the options
Explanation: ***Vitamin-E*** - **Vitamin-E** is an **antioxidant** vitamin that primarily protects cells from oxidative damage. - It does not play a direct role in **bone metabolism** or the prevention of osteoporosis. *Calcium* - **Calcium** is a fundamental component of bone tissue and is essential for maintaining **bone density** [1]. - Adequate calcium intake is crucial for **osteoporosis prevention**, especially in postmenopausal women [1], [2]. *Vit.D* - **Vitamin D** is essential for **calcium absorption** in the gut and its incorporation into bones. - Without sufficient Vitamin D, calcium cannot be effectively utilized, leading to compromised **bone health**. *None of the options* - This option is incorrect because Vitamin E does not contribute to osteoporosis prevention, making it the correct answer to the "EXCEPT" question. - Calcium and Vitamin D are both vital for bone strength, so stating that none of the options fit would be inaccurate [1].
Question 6: Which clinical sign is consistently present in all bone fractures?
- A. Tenderness
- B. None of the options (Correct Answer)
- C. Crepitus
- D. Abnormal mobility
Explanation: ***None of the options*** - No single clinical sign is **consistently present** in all bone fractures, as presentations vary depending on the bone, fracture type, and patient factors. - While many signs are common, some fractures can be **subtle or atypical**, making a single universal sign an impossibility. *Crepitus* - **Crepitus** (a grating or crackling sound/sensation) occurs when fractured bone ends rub against each other. - It is not always present, especially in **impacted fractures** or when displacement is minimal, and often indicates significant instability. *Tenderness* - While localized **tenderness** is a very common sign of fracture, it is not universally present in all cases. - For example, in **stress fractures** or some pathological fractures, pain may be diffuse or less acutely localized. *Abnormal mobility* - **Abnormal mobility** at a site not normally a joint is a strong indication of a complete fracture and significant displacement. - However, it is absent in **incomplete fractures** (e.g., greenstick, hairline), impacted fractures, or when the fracture is well-stabilized.
Question 7: Osteoporosis in menopause typically affects
- A. Periosteum
- B. Compact bone
- C. Metaphysis
- D. Trabecular bone (Correct Answer)
Explanation: ***Trabecular bone*** - **Trabecular bone**, also known as **spongy bone**, is metabolically more active and has a higher surface-to-volume ratio, making it more susceptible to rapid bone loss due to estrogen deficiency in menopause [1][2]. - Common fracture sites associated with menopausal osteoporosis, such as the **vertebrae** and **distal radius**, are rich in trabecular bone [2]. *Periosteum* - The **periosteum** is a membrane covering the outer surface of bones, primarily involved in bone growth, repair, and nutrient supply, not the primary site of bone loss in osteoporosis. - While it plays a role in bone metabolism, it is not directly targeted by the bone loss mechanism seen in menopausal osteoporosis affecting bone density. *Compact bone* - **Compact bone**, or cortical bone, is denser and forms the outer layer of most bones; it remodels at a slower rate than trabecular bone [1]. - While compact bone is affected in later stages of osteoporosis, the initial and more rapid bone loss in menopause primarily occurs in the more metabolically active trabecular bone [1][2]. *Metaphysis* - The **metaphysis** is the wide portion of a long bone between the epiphysis and the diaphysis, containing both compact and trabecular bone. - While fractures in this region can occur, the term refers to a region of the bone, not a specific type of bone tissue preferentially affected by menopausal osteoporosis more than trabecular bone itself. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Osteoarticular And Connective Tissue Disease, pp. 662-663. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Bones, Joints, and Soft Tissue Tumors, pp. 1190-1191.
Question 8: The compression fracture is commonest in
- A. Upper thoracic spine
- B. Cervical spine
- C. Lumbosacral region
- D. Lower thoracic spine (Correct Answer)
Explanation: ***Lower thoracic spine*** - The **thoracolumbar junction (T11-L2)** is the most common site for compression fractures due to its high biomechanical stress, transitioning from stiff thoracic spine to more flexible lumbar spine. - This area is particularly vulnerable to axial loading and flexion injuries because it's a zone of increased mobility and stress concentration. *Upper thoracic spine* - The upper thoracic spine has **rib cage support** and less mobility, making fractures here less common without significant traumatic force. - Fractures in this region often indicate a **high-energy injury** due to its inherent stability. *Cervical spine* - While cervical fractures can be serious, they typically result from **high-energy trauma** and are less commonly simple compression fractures compared to the thoracolumbar region. - The **cervical spine** is more prone to **burst fractures** or **dislocations** from flexion-distraction or extension injuries. *Lumbosacral region* - The **sacrum and coccyx** are relatively stable bone structures and are less prone to common compression fractures unless there is severe trauma or significant bone weakening (e.g., severe osteoporosis). - While lumbar compression fractures do occur, the **junctional region** between the thoracic and lumbar spine (lower thoracic/upper lumbar) is statistically more frequent.
Question 9: Which of the following is not typically associated with osteogenesis imperfecta?
- A. Blue sclera
- B. Lax ligament
- C. Bilateral Hip dislocation (Correct Answer)
- D. Osteoporosis
Explanation: ***Bilateral Hip dislocation*** - While hip dislocations can occur in severe cases due to bone fragility, **bilateral hip dislocation** is not a characteristic or typical primary association with osteogenesis imperfecta. - The underlying issue is primarily **bone fragility** leading to fractures, not inherent joint instability or malformation causing bilateral dislocation. *Blue sclera* - **Blue sclera** is a classic sign of osteogenesis imperfecta, caused by the thinness of the sclera allowing the underlying choroid vessels to show through. - This is due to a defect in **Type I collagen** synthesis, which affects not only bones but also other connective tissues including the sclera. *Lax ligament* - **Lax ligaments** are common in osteogenesis imperfecta due to the generalized **connective tissue defect**, particularly involving Type I collagen. - This can contribute to joint instability, *hypermobility*, and an increased risk of sprains. *Osteoporosis* - **Osteoporosis** with reduced bone mineral density is a hallmark feature of osteogenesis imperfecta, leading to **fragile bones** and recurrent fractures. - The genetic defect in **Type I collagen** impairs bone matrix formation, resulting in weak and brittle bones.
Question 10: A 60-year-old elderly female with a previous history of a Colles fracture is now complaining of backache. Which of the following statements regarding the treatment of this patient is incorrect?
- A. Oral vitamin D3 is given along with oral calcium
- B. Teriparatide should be started before supplementing bisphosphonates (Correct Answer)
- C. Calcium requirement is 1200 mg per day
- D. Bisphosphonates can be given for 3-5 years depending on patient response and risk factors
Explanation: ***Teriparatide should be started before supplementing bisphosphonates*** - This statement is incorrect because **bisphosphonates are typically the first-line treatment** for osteoporosis, especially in patients with a history of fragility fractures like a Colles fracture. - **Teriparatide**, an anabolic agent, is usually reserved for patients with very severe osteoporosis, those who have failed bisphosphonate therapy, or those with highly accelerated bone loss. *Oral vitamin D3 is given along with oral calcium* - This is a routine and **correct practice in osteoporosis management** as calcium and vitamin D are essential for bone health. - **Vitamin D** aids in calcium absorption from the gut, and both are crucial for bone mineralization and density. *Calcium requirement is 1200 mg per day* - The recommended daily **calcium intake for postmenopausal women** and elderly individuals with osteoporosis is typically around 1200 mg. - This amount helps to maintain skeletal health and reduce the risk of fractures. *Bisphosphonates can be given for 3-5 years depending on patient response and risk factors* - This statement is correct, as **bisphosphonates are commonly prescribed for 3-5 years** to reduce fracture risk in osteoporosis. - A **"drug holiday"** may be considered after this period, depending on the patient's fracture risk and bone mineral density.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free